BEIGENE, LTD. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130 USD | -1.45% |
|
-8.36% | -28.21% |
| Apr. 17 | BeiGene to Award Shares Worth $15 Million to 11 Directors | MT |
| Apr. 11 | Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech | MT |
Financials (USD)
| Sales 2024 * | 3.08B | Sales 2025 * | 3.93B | Capitalization | 13.79B |
|---|---|---|---|---|---|
| Net income 2024 * | -892M | Net income 2025 * | -358M | EV / Sales 2024 * | 3.99 x |
| Net cash position 2024 * | 1.48B | Net cash position 2025 * | 1.13B | EV / Sales 2025 * | 3.22 x |
| P/E ratio 2024 * |
-15.4
x | P/E ratio 2025 * |
-40.8
x | Employees | 10,600 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.21% |
More Fundamentals
* Assessed data
More news
Latest transcript on BeiGene, Ltd.
More recommendations
More press releases
More news
| 1 day | +0.08% | ||
| 1 week | -9.70% | ||
| Current month | -15.62% | ||
| 1 month | -21.69% | ||
| 3 months | -20.19% | ||
| 6 months | -21.24% | ||
| Current year | -26.84% |
1 week
131.28
142.63
1 month
131.28170.36
Current year
131.28184.80
1 year
131.28266.67
3 years
118.18426.56
5 years
113.01426.56
10 years
22.51426.56
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.48% | 4 M€ | -27.92% | ||
| 1.49% | 0 M€ | 0.00% | - | |
| 1.39% | 9 M€ | -4.31% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 129.6 | -1.77% | 48 708 |
| 24-04-18 | 132 | +0.08% | 125,955 |
| 24-04-17 | 131.9 | -1.63% | 200,058 |
| 24-04-16 | 134 | -3.14% | 308,982 |
| 24-04-15 | 138.4 | -2.05% | 228,159 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Brutonâs Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
132
USD
Average target price
268.6
USD
Spread / Average Target
+103.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.84% | 13.79B | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.44% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B | |
| -21.69% | 8.57B |
- Stock Market
- Equities
- BGNE Stock
